Is Verrica Pharmaceuticals Inc. (VRCA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 54.1% / 30% | 54.6% / 30% | 0.1% / 30% | 18.73% / 5% | ✗ NOT HALAL |
| DJIM | 54.1% / 33% | 54.6% / 33% | 0.1% / 33% | 18.73% / 5% | ✗ NOT HALAL |
| MSCI | 84.9% / 33% | 85.6% / 33% | 0.1% / 33% | 18.73% / 5% | ✗ NOT HALAL |
| S&P | 54.1% / 33% | 54.6% / 33% | 0.1% / 33% | 18.73% / 5% | ✗ NOT HALAL |
| FTSE | 84.9% / 33% | 85.6% / 33% | 0.1% / 50% | 18.73% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 65.4% | |
| Operating Margin | -136.4% | |
| Net Margin | -50.3% | |
| Return on Equity (ROE) | -240.4% | |
| Return on Assets (ROA) | -14.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$18M |
| Free Cash Flow | -$18M |
| Total Debt | $2M |
| Debt-to-Equity | 6.6 |
| Current Ratio | 2.6 |
| Total Assets | $47M |
Price & Trading
| Last Close | $4.39 |
| 50-Day MA | $6.15 |
| 200-Day MA | $6.00 |
| Avg Volume | 154K |
| Beta | 1.5 |
|
52-Week Range
$3.28
| |
About Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Verrica Pharmaceuticals Inc. (VRCA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Verrica Pharmaceuticals Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Verrica Pharmaceuticals Inc.'s debt ratio?
Verrica Pharmaceuticals Inc.'s debt ratio is 54.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 84.9%.
What are Verrica Pharmaceuticals Inc.'s key financial metrics?
Verrica Pharmaceuticals Inc. has a market capitalization of $75M, and revenue of $36M. The company maintains a gross margin of 65.4% and a net margin of -50.3%. Return on equity stands at -240.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.